Risk factors for low adherence to methylphenidate treatment in pediatric patients with attention-deficit/hyperactivity disorder

Abstract Poor adherence is a major concern in the treatment of attention-deficit/hyperactivity disorder (ADHD). The objective of this study was to evaluate factors linked to early interruption of and low adherence to treatment with osmotic-release oral system methylphenidate hydrochloride (OROS-MPH)...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Asami Ishizuya, Minori Enomoto, Hisateru Tachimori, Hidehiko Takahashi, Genichi Sugihara, Shingo Kitamura, Kazuo Mishima
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/7049cd516c5a4bc6a30535f2b68cddc3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7049cd516c5a4bc6a30535f2b68cddc3
record_format	dspace
spelling	oai:doaj.org-article:7049cd516c5a4bc6a30535f2b68cddc32021-12-02T10:49:29ZRisk factors for low adherence to methylphenidate treatment in pediatric patients with attention-deficit/hyperactivity disorder10.1038/s41598-021-81416-z2045-2322https://doaj.org/article/7049cd516c5a4bc6a30535f2b68cddc32021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-81416-zhttps://doaj.org/toc/2045-2322Abstract Poor adherence is a major concern in the treatment of attention-deficit/hyperactivity disorder (ADHD). The objective of this study was to evaluate factors linked to early interruption of and low adherence to treatment with osmotic-release oral system methylphenidate hydrochloride (OROS-MPH) in pediatric patients with ADHD. A total of 1353 young people (age 6–17 years) with a diagnosis of ADHD who newly started OROS-MPH were extracted from the pharmacoepidemiological data of 3 million people in Japan. The cohort was retrospectively surveyed every month for 12 months. Ten possible risk factors were extracted from the data and analyzed by multivariable logistic regression. Sensitivity analysis was conducted to ensure the robustness of the analysis. The results revealed that treatment adherence was generally poor, with a tendency for discontinuation in the early stage. Multivariable logistic regression results showed that adherence is reduced by female sex, lower starting dose, and concomitant atomoxetine or hypnotics. These findings may help clinicians to predict the risk of poor adherence in the early stage of treatment and improve not only patients’ symptoms, but also their quality of life.Asami IshizuyaMinori EnomotoHisateru TachimoriHidehiko TakahashiGenichi SugiharaShingo KitamuraKazuo MishimaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Asami Ishizuya Minori Enomoto Hisateru Tachimori Hidehiko Takahashi Genichi Sugihara Shingo Kitamura Kazuo Mishima Risk factors for low adherence to methylphenidate treatment in pediatric patients with attention-deficit/hyperactivity disorder
description	Abstract Poor adherence is a major concern in the treatment of attention-deficit/hyperactivity disorder (ADHD). The objective of this study was to evaluate factors linked to early interruption of and low adherence to treatment with osmotic-release oral system methylphenidate hydrochloride (OROS-MPH) in pediatric patients with ADHD. A total of 1353 young people (age 6–17 years) with a diagnosis of ADHD who newly started OROS-MPH were extracted from the pharmacoepidemiological data of 3 million people in Japan. The cohort was retrospectively surveyed every month for 12 months. Ten possible risk factors were extracted from the data and analyzed by multivariable logistic regression. Sensitivity analysis was conducted to ensure the robustness of the analysis. The results revealed that treatment adherence was generally poor, with a tendency for discontinuation in the early stage. Multivariable logistic regression results showed that adherence is reduced by female sex, lower starting dose, and concomitant atomoxetine or hypnotics. These findings may help clinicians to predict the risk of poor adherence in the early stage of treatment and improve not only patients’ symptoms, but also their quality of life.
format	article
author	Asami Ishizuya Minori Enomoto Hisateru Tachimori Hidehiko Takahashi Genichi Sugihara Shingo Kitamura Kazuo Mishima
author_facet	Asami Ishizuya Minori Enomoto Hisateru Tachimori Hidehiko Takahashi Genichi Sugihara Shingo Kitamura Kazuo Mishima
author_sort	Asami Ishizuya
title	Risk factors for low adherence to methylphenidate treatment in pediatric patients with attention-deficit/hyperactivity disorder
title_short	Risk factors for low adherence to methylphenidate treatment in pediatric patients with attention-deficit/hyperactivity disorder
title_full	Risk factors for low adherence to methylphenidate treatment in pediatric patients with attention-deficit/hyperactivity disorder
title_fullStr	Risk factors for low adherence to methylphenidate treatment in pediatric patients with attention-deficit/hyperactivity disorder
title_full_unstemmed	Risk factors for low adherence to methylphenidate treatment in pediatric patients with attention-deficit/hyperactivity disorder
title_sort	risk factors for low adherence to methylphenidate treatment in pediatric patients with attention-deficit/hyperactivity disorder
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/7049cd516c5a4bc6a30535f2b68cddc3
work_keys_str_mv	AT asamiishizuya riskfactorsforlowadherencetomethylphenidatetreatmentinpediatricpatientswithattentiondeficithyperactivitydisorder AT minorienomoto riskfactorsforlowadherencetomethylphenidatetreatmentinpediatricpatientswithattentiondeficithyperactivitydisorder AT hisaterutachimori riskfactorsforlowadherencetomethylphenidatetreatmentinpediatricpatientswithattentiondeficithyperactivitydisorder AT hidehikotakahashi riskfactorsforlowadherencetomethylphenidatetreatmentinpediatricpatientswithattentiondeficithyperactivitydisorder AT genichisugihara riskfactorsforlowadherencetomethylphenidatetreatmentinpediatricpatientswithattentiondeficithyperactivitydisorder AT shingokitamura riskfactorsforlowadherencetomethylphenidatetreatmentinpediatricpatientswithattentiondeficithyperactivitydisorder AT kazuomishima riskfactorsforlowadherencetomethylphenidatetreatmentinpediatricpatientswithattentiondeficithyperactivitydisorder
_version_	1718396596714995712

Risk factors for low adherence to methylphenidate treatment in pediatric patients with attention-deficit/hyperactivity disorder

Ejemplares similares